1
|
Margonato D, Rizza V, Ingallina G, Preda A, Ancona F, Belli M, Godino C, Agricola E, Della Bella P, Grasso C, Contarini M, Mazzone P. Left atrial appendage occlusion in the absence of intraprocedural product specialist monitoring: is it time to proceed alone? Results from a multicenter real-world experience. Front Cardiovasc Med 2023; 10:1172005. [PMID: 37383696 PMCID: PMC10293837 DOI: 10.3389/fcvm.2023.1172005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2023] [Accepted: 05/31/2023] [Indexed: 06/30/2023] Open
Abstract
Background Percutaneous left atrial appendage occlusion (LAAO) presents many technical complex features, and it is often performed under the intraprocedural surveillance of a product specialist (PS). Our aim is to assess whether LAAO is equally safe and effective when performed in high-volume centers without PS support. Methods Intraprocedural results and long-term outcome were retrospectively assessed in 247 patients who underwent LAAO without intraprocedural PS monitoring between January 2013 and January 2022 at three different hospitals. This cohort was then matched to a population who underwent LAAO with PS surveillance. The primary end point was all-cause mortality at 1 year. The secondary end point was a composite of cardiovascular mortality plus nonfatal ischemic stroke occurrence at 1 year. Results Of the 247 study patients, procedural success was achieved in 243 patients (98.4%), with only 1 (0.4%) intraprocedural death. After matching, we did not identify any significant difference between the two groups in terms of procedural time (70 ± 19 min vs. 81 ± 30 min, p = 0.106), procedural success (98.4% vs. 96.7%, p = 0.242), and procedure-related ischemic stroke (0.8% vs. 1.2%, p = 0.653). Compared to the matched cohort, a significant higher dosage of contrast was used during procedures without specialist supervision (98 ± 19 vs. 43 ± 21, p < 0.001), but this was not associated with a higher postprocedural acute kidney injury occurrence (0.8% vs. 0.4%, p = 0.56). At 1 year, the primary and the secondary endpoints occurred in 21 (9%) and 11 (4%) of our cohort, respectively. Kaplan-Meier curves showed no significant difference in both primary (p = 0.85) and secondary (p = 0.74) endpoint occurrence according to intraprocedural PS monitoring. Conclusions Our results show that LAAO, despite the absence of intraprocedural PS monitoring, remains a long-term safe and effective procedure, when performed in high-volume centers.
Collapse
Affiliation(s)
- Davide Margonato
- Department of Cardiovascular Imaging, IRCCS San Raffaele Hospital and Vita-Salute University, Milan, Italy
| | - Vincenzo Rizza
- Department of Cardiovascular Imaging, IRCCS San Raffaele Hospital and Vita-Salute University, Milan, Italy
| | - Giacomo Ingallina
- Department of Cardiovascular Imaging, IRCCS San Raffaele Hospital and Vita-Salute University, Milan, Italy
| | - Alberto Preda
- Department of Cardiac Electrophysiology and Arrhythmology, IRCCS San Raffaele Hospital and Vita-Salute University, Milan, Italy
| | - Francesco Ancona
- Department of Cardiovascular Imaging, IRCCS San Raffaele Hospital and Vita-Salute University, Milan, Italy
| | - Martina Belli
- Department of Cardiovascular Imaging, IRCCS San Raffaele Hospital and Vita-Salute University, Milan, Italy
| | - Cosmo Godino
- Department of Clinical Cardiology, IRCCS San Raffaele Hospital and Vita-Salute University, Milan, Italy
| | - Eustachio Agricola
- Department of Cardiovascular Imaging, IRCCS San Raffaele Hospital and Vita-Salute University, Milan, Italy
| | - Paolo Della Bella
- Department of Cardiac Electrophysiology and Arrhythmology, IRCCS San Raffaele Hospital and Vita-Salute University, Milan, Italy
| | - Carmelo Grasso
- Department of Cardiology, C.A.S.T., Azienda Ospedaliero Universitaria Policlinico “G. Rodolico-San Marco”, University of Catania, Catania, Italy
| | - Marco Contarini
- Department of Interventional Cardiology, Umberto I Hospital, Syracuse, Italy
| | - Patrizio Mazzone
- Department of Cardiac Electrophysiology and Arrhythmology, IRCCS San Raffaele Hospital and Vita-Salute University, Milan, Italy
| |
Collapse
|
2
|
Saw J, Holmes DR, Cavalcante JL, Freeman JV, Goldsweig AM, Kavinsky CJ, Moussa ID, Munger TM, Price MJ, Reisman M, Sherwood MW, Turi ZG, Wang DD, Whisenant BK. SCAI/HRS Expert Consensus Statement on Transcatheter Left Atrial Appendage Closure. JACC Cardiovasc Interv 2023; 16:1384-1400. [PMID: 36990858 DOI: 10.1016/j.jcin.2023.01.011] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/31/2023]
Abstract
Exclusion of the left atrial appendage to reduce thromboembolic risk related to atrial fibrillation was first performed surgically in 1949. Over the past 2 decades, the field of transcatheter endovascular left atrial appendage closure (LAAC) has rapidly expanded, with a myriad of devices approved or in clinical development. The number of LAAC procedures performed in the United States and worldwide has increased exponentially since the Food and Drug Administration approval of the WATCHMAN (Boston Scientific) device in 2015. The Society for Cardiovascular Angiography & Interventions (SCAI) has previously published statements in 2015 and 2016 providing societal overview of the technology and institutional and operator requirements for LAAC. Since then, results from several important clinical trials and registries have been published, technical expertise and clinical practice have matured over time, and the device and imaging technologies have evolved. Therefore, SCAI prioritized the development of an updated consensus statement to provide recommendations on contemporary, evidence-based best practices for transcatheter LAAC focusing on endovascular devices.
Collapse
Affiliation(s)
- Jacqueline Saw
- Division of Cardiology, Vancouver General Hospital, University of British Columbia, Canada.
| | - David R Holmes
- Department of Cardiovascular Medicine, Mayo Clinic Health System Rochester, Rochester, Minnesota
| | - João L Cavalcante
- Department of Cardiology, Minneapolis Heart Institute, Minneapolis, Minnesota
| | - James V Freeman
- Section of Cardiovascular Medicine, Yale University, New Haven, Connecticut
| | - Andrew M Goldsweig
- Division of Cardiovascular Medicine, The University of Nebraska Medical Center, Omaha, Nebraska
| | | | - Issam D Moussa
- Carle Heart and Vascular Institute, Carle Illinois College of Medicine, Urbana, Illinois
| | - Thomas M Munger
- Department of Cardiovascular Medicine, Mayo Clinic Health System Rochester, Rochester, Minnesota
| | - Matthew J Price
- Division of Cardiovascular Diseases, Scripps Green Hospital, La Jolla, California
| | - Mark Reisman
- Division of Cardiology, Weill Cornell Medical Center, New York, New York
| | | | - Zoltan G Turi
- Center for Structural and Congenital Heart Disease, Hackensack University Medical Center, Hackensack, New Jersey
| | - Dee Dee Wang
- Center for Structural Heart Disease, Henry Ford Health System, Detroit, Michigan
| | | |
Collapse
|
3
|
Saw J, Holmes DR, Cavalcante JL, Freeman JV, Goldsweig AM, Kavinsky CJ, Moussa ID, Munger TM, Price MJ, Reisman M, Sherwood MW, Turi ZG, Wang DD, Whisenant BK. SCAI/HRS expert consensus statement on transcatheter left atrial appendage closure. Heart Rhythm 2023; 20:e1-e16. [PMID: 36990925 DOI: 10.1016/j.hrthm.2023.01.007] [Citation(s) in RCA: 13] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/31/2023]
Abstract
Exclusion of the left atrial appendage to reduce thromboembolic risk related to atrial fibrillation was first performed surgically in 1949. Over the past 2 decades, the field of transcatheter endovascular left atrial appendage closure (LAAC) has rapidly expanded, with a myriad of devices approved or in clinical development. The number of LAAC procedures performed in the United States and worldwide has increased exponentially since the Food and Drug Administration approval of the WATCHMAN (Boston Scientific) device in 2015. The Society for Cardiovascular Angiography & Interventions (SCAI) has previously published statements in 2015 and 2016 providing societal overview of the technology and institutional and operator requirements for LAAC. Since then, results from several important clinical trials and registries have been published, technical expertise and clinical practice have matured over time, and the device and imaging technologies have evolved. Therefore, SCAI prioritized the development of an updated consensus statement to provide recommendations on contemporary, evidence-based best practices for transcatheter LAAC focusing on endovascular devices.
Collapse
Affiliation(s)
- Jacqueline Saw
- Division of Cardiology, Vancouver General Hospital, University of British Columbia, Canada.
| | - David R Holmes
- Department of Cardiovascular Medicine, Mayo Clinic Health System Rochester, Rochester, Minnesota
| | - João L Cavalcante
- Department of Cardiology, Minneapolis Heart Institute, Minneapolis, Minnesota
| | - James V Freeman
- Section of Cardiovascular Medicine, Yale University, New Haven, Connecticut
| | - Andrew M Goldsweig
- Division of Cardiovascular Medicine, The University of Nebraska Medical Center, Omaha, Nebraska
| | | | - Issam D Moussa
- Carle Heart and Vascular Institute, Carle Illinois College of Medicine, Urbana, Illinois
| | - Thomas M Munger
- Department of Cardiovascular Medicine, Mayo Clinic Health System Rochester, Rochester, Minnesota
| | - Matthew J Price
- Division of Cardiovascular Diseases, Scripps Green Hospital, La Jolla, California
| | - Mark Reisman
- Division of Cardiology, Weill Cornell Medical Center, New York, New York
| | | | - Zoltan G Turi
- Center for Structural and Congenital Heart Disease, Hackensack University Medical Center, Hackensack, New Jersey
| | - Dee Dee Wang
- Center for Structural Heart Disease, Henry Ford Health System, Detroit, Michigan
| | | |
Collapse
|
4
|
Su F, Gao C, Liu J, Ning Z, He B, Liu Y, Xu Y, Yang B, Li Y, Zhang J, Zhao X, Zhang Y, Hu H, Du X, Xie R, Zhou L, Zeng J, Ruan Z, Liu H, Guo J, Wang R, Garg S, Soliman O, Holmes DR, Serruys PW, Tao L. Periprocedural Outcomes Associated With Use of a Left Atrial Appendage Occlusion Device in China. JAMA Netw Open 2022; 5:e2214594. [PMID: 35639378 PMCID: PMC9157261 DOI: 10.1001/jamanetworkopen.2022.14594] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
IMPORTANCE Left atrial appendage occlusion (LAAO) has emerged as an alternative to anticoagulation for patients with atrial fibrillation. However, the performance of LAAO among East Asian patients is unknown. OBJECTIVE To document the procedural success rate and configurations, major adverse event rates, and antithrombotic medication regimens during and after LAAO procedures among patients in China. DESIGN, SETTING, AND PARTICIPANTS In this cohort study, consecutive patients from 39 Chinese centers undergoing LAAO were prospectively enrolled between April 1, 2019, and October 31, 2020. Periprocedural and intraprocedural techniques and postprocedural medications were left to the surgeon's discretion. Data were analyzed from July 1 to November 1, 2021. EXPOSURE LAAO for patients with atrial fibrillation. MAIN OUTCOMES AND MEASURES The main outcomes were procedural success and complication rates periprocedure and major adverse event rates of death, stroke, systemic embolism, and bleeding events at 30 days postprocedure; the composite end point of death, stroke, and systemic embolism was also analyzed. Unadjusted and multivariable-adjusted logistic regression analyses were performed to assess the associations of periprocedural techniques (types of anesthesia, intraprocedural imaging modalities, and combined ablation procedure) with 30-day adverse events. RESULTS Among 3096 enrolled participants, 1782 participants (57.6%) were men, and the mean (SD) age was 69 (9) years. Participants had a high risk of stroke (mean [SD] cardiovascular risk score, 4.0 [1.8]) and a moderate-to-high risk of bleeding (mean [SD] bleeding risk score, 2.4 [1.2]). A total of 1287 procedures (41.6%) were performed under local anesthesia, while 493 procedures (15.9%) used only fluoroscopy guidance. In 1297 procedures (41.9%), LAAO implantation was combined with radiofrequency ablation or cryoablation for atrial fibrillation. Procedural success was achieved in 3032 patients (97.9%). At 30-day follow-up, the rate of the composite end point of death, stroke, or systemic embolism was 0.52% (95% CI, 0.32%-0.84%), and the rate of any life-threatening or major bleeding was 1.23% (95% CI, 0.90%-1.68%). No significant associations were observed between the procedural success or 30-day adverse events and the types of anesthesia (general or local), intraprocedural imaging (transesophageal echocardiography, fluoroscopy, or intracardiac echocardiography), or whether a combined ablation procedure was performed or not. In centers performing at least 40 procedures per year, compared with those performing fewer than 40 procedures per year, procedural success was significantly higher (adjusted odd ratio [aOR], 1.97; 95% CI, 1.01-3.53; P = .02) and risk of life-threatening or major bleeding was significantly lower (aOR, 0.42; 95% CI, 0.21-0.87; P = .02). CONCLUSIONS AND RELEVANCE These findings suggest that patients with a high risk of stroke and moderate to high risk of bleeding who underwent implantation of a LAAO device in Chinese centers had high rates of procedural success and low rates of short-term ischemic and bleeding events.
Collapse
Affiliation(s)
- Fangju Su
- Department of Cardiology, Xijing Hospital, Xi’an, China
- Department of Cardiology, The 940th Hospital, Lanzhou, China
| | - Chao Gao
- Department of Cardiology, Xijing Hospital, Xi’an, China
| | - Jianzheng Liu
- Department of Cardiology, Xijing Hospital, Xi’an, China
| | - Zhongping Ning
- Department of Cardiology, Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital, Shanghai, China
| | - Beng He
- Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
| | - Yi Liu
- Department of Cardiology, Xijing Hospital, Xi’an, China
| | - Yawei Xu
- Department of Cardiology, Shanghai Tenth People’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Bing Yang
- Department of Cardiology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China
| | - Yuechun Li
- Department of Cardiology, Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, China
| | - Junfeng Zhang
- Department of Cardiology, Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Xianxian Zhao
- Department of Cardiology, Changhai Hospital, Navy Military Medical University, Shanghai, China
| | - Yushun Zhang
- Department of Cardiology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
| | - Hao Hu
- Department of Cardiology, The Second Affiliated Hospital of Lanzhou University, Lanzhou, China
| | - Xianfeng Du
- Department of Cardiology, Arrhythmia Center, Ningbo First Hospital, Ningbo, China
| | - Ruiqin Xie
- Department of Cardiology, The Second Affiliated Hospital of Hebei Medical University, Shijiazhuang, China
| | - Ling Zhou
- Department of Cardiology, Nanjing First Hospital, Nanjing, China
| | - Jie Zeng
- Department of Cardiology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China
| | - Zhongbao Ruan
- Department of Cardiology, Taizhou People’s Hospital, Taizhou, China
| | - Haitao Liu
- Department of Cardiology, Xijing Hospital, Xi’an, China
| | - Jun Guo
- Department of Cardiology, Senior Department of Cardiology, the Sixth Medical Center of PLA General Hospital, Beijing, China
| | - Rutao Wang
- Department of Cardiology, Xijing Hospital, Xi’an, China
| | - Scot Garg
- Department of Cardiology, Royal Blackburn Hospital, Blackburn, United Kingdom
| | - Osama Soliman
- Department of Cardiology, National University of Ireland, Galway, Ireland
| | - David R. Holmes
- Department of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota
| | - Patrick W. Serruys
- Department of Cardiology, National University of Ireland, Galway, Ireland
| | - Ling Tao
- Department of Cardiology, Xijing Hospital, Xi’an, China
| |
Collapse
|
5
|
Naidu SS, Abbott JD, Bagai J, Blankenship J, Garcia S, Iqbal SN, Kaul P, Khuddus MA, Kirkwood L, Manoukian SV, Patel MR, Skelding K, Slotwiner D, Swaminathan RV, Welt FG, Kolansky DM. SCAI expert consensus update on best practices in the cardiac catheterization laboratory: This statement was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), and the Heart Rhythm Society (HRS) in April 2021. Catheter Cardiovasc Interv 2021; 98:255-276. [PMID: 33909349 DOI: 10.1002/ccd.29744] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/23/2021] [Accepted: 04/23/2021] [Indexed: 12/28/2022]
Abstract
The current document commissioned by the Society for Cardiovascular Angiography and Interventions (SCAI) and endorsed by the American College of Cardiology, the American Heart Association, and Heart Rhythm Society represents a comprehensive update to the 2012 and 2016 consensus documents on patient-centered best practices in the cardiac catheterization laboratory. Comprising updates to staffing and credentialing, as well as evidence-based updates to the pre-, intra-, and post-procedural logistics, clinical standards and patient flow, the document also includes an expanded section on CCL governance, administration, and approach to quality metrics. This update also acknowledges the collaboration with various specialties, including discussion of the heart team approach to management, and working with electrophysiology colleagues in particular. It is hoped that this document will be utilized by hospitals, health systems, as well as regulatory bodies involved in assuring and maintaining quality, safety, efficiency, and cost-effectiveness of patient throughput in this high volume area.
Collapse
Affiliation(s)
- Srihari S Naidu
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, New York, USA
| | - J Dawn Abbott
- Cardiovascular Institute of Lifespan, Division of Cardiology, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA
| | - Jayant Bagai
- Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - James Blankenship
- Cardiology Division, The University of New Mexico, Albuquerque, New Mexico, USA
| | | | - Sohah N Iqbal
- Mass General Brigham Salem Hospital, Salem, Massachusetts, USA
| | | | - Matheen A Khuddus
- The Cardiac and Vascular Institute and North Florida Regional Medical Center, Gainesville, Florida, USA
| | - Lorrena Kirkwood
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, New York, USA
| | | | - Manesh R Patel
- Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina, USA
| | | | - David Slotwiner
- Division of Cardiology, New York Presbyterian, Weill Cornell Medicine Population Health Sciences, Queens, New York, USA
| | - Rajesh V Swaminathan
- Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina, USA
| | - Frederick G Welt
- Division of Cardiovascular Medicine, University of Utah Health, Salt Lake City, Utah, USA
| | - Daniel M Kolansky
- Division of Cardiovascular Medicine, Perelman School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
| |
Collapse
|
6
|
Infeld MM, Silverman DN, Lustgarten DL. Left Atrial Appendage Closure: A Safe and Effective Alternative to Anticoagulation? J Innov Card Rhythm Manag 2019; 10:3486-3493. [PMID: 32494404 PMCID: PMC7252882 DOI: 10.19102/icrm.2019.100107] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2018] [Accepted: 06/01/2018] [Indexed: 11/06/2022] Open
Abstract
To date, left atrial appendage closure (LAAC) devices continue to be assessed as an intuitive alternative to oral anticoagulant therapy to prevent embolic complications in patients with atrial fibrillation. Concerns remain about the up-front risks associated with device implantation as well as device efficacy in preventing embolic events as compared with anticoagulation. Currently, LAAC devices serve as a potential alternative to long-term anticoagulation with the benefit of decreased bleeding risk but with less protection against ischemic events. An individualized risk-benefit analysis with regard to stroke possibility, bleeding likelihood with long-term anticoagulation, the risks of an invasive procedure, and the risks associated with having a lifelong intracardiac device should be performed to guide careful patient selection for this operation.
Collapse
Affiliation(s)
- Margaret M Infeld
- University of Vermont Medical Center, Burlington, VT, USA.,University of Vermont College of Medicine, Burlington, VT, USA
| | - Daniel N Silverman
- University of Vermont Medical Center, Burlington, VT, USA.,University of Vermont College of Medicine, Burlington, VT, USA
| | - Daniel L Lustgarten
- University of Vermont Medical Center, Burlington, VT, USA.,University of Vermont College of Medicine, Burlington, VT, USA
| |
Collapse
|
7
|
Jazayeri MA, Vuddanda V, Parikh V, Lavu M, Atkins D, Reddy YM, Nath J, Lakkireddy DR. Five years of keeping a watch on the left atrial appendage-how has the WATCHMAN fared? J Thorac Dis 2017; 8:E1726-E1733. [PMID: 28149625 DOI: 10.21037/jtd.2016.12.57] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Left atrial appendage closure (LAAC) is a promising site-directed therapy for stroke prevention in patients with non-valvular atrial fibrillation (AF) who are ineligible or contraindicated for long-term oral anticoagulation. A variety of LAAC modalities are available, including percutaneous endocardial occluder devices such as WATCHMANTM (Boston Scientific Corp., Marlborough, MA, USA), and an ever-increasing body of evidence is helping to define the optimal use of each technique. Similarly increased experience with LAAC has revealed challenges such as device-related thrombi and peri-device leaks for which the long-term significance and appropriate management are areas of active investigation. We review the evolution and long-term outcomes with the WATCHMANTM device with particular emphasis on the nuances of its use and its role in the broader landscape of appendageology.
Collapse
Affiliation(s)
- Mohammad-Ali Jazayeri
- Division of Cardiovascular Diseases, Center for Excellence in Atrial Fibrillation & EP Research, Bloch Heart Rhythm Center, Cardiovascular Research Institute, University of Kansas Medical Center, Mid America Cardiology, University of Kansas Hospitals, Kansas City, KS, USA
| | - Venkat Vuddanda
- Division of Cardiovascular Diseases, Center for Excellence in Atrial Fibrillation & EP Research, Bloch Heart Rhythm Center, Cardiovascular Research Institute, University of Kansas Medical Center, Mid America Cardiology, University of Kansas Hospitals, Kansas City, KS, USA
| | - Valay Parikh
- Division of Cardiovascular Diseases, Center for Excellence in Atrial Fibrillation & EP Research, Bloch Heart Rhythm Center, Cardiovascular Research Institute, University of Kansas Medical Center, Mid America Cardiology, University of Kansas Hospitals, Kansas City, KS, USA
| | - Madhav Lavu
- Division of Cardiovascular Diseases, Center for Excellence in Atrial Fibrillation & EP Research, Bloch Heart Rhythm Center, Cardiovascular Research Institute, University of Kansas Medical Center, Mid America Cardiology, University of Kansas Hospitals, Kansas City, KS, USA
| | - Donita Atkins
- Division of Cardiovascular Diseases, Center for Excellence in Atrial Fibrillation & EP Research, Bloch Heart Rhythm Center, Cardiovascular Research Institute, University of Kansas Medical Center, Mid America Cardiology, University of Kansas Hospitals, Kansas City, KS, USA
| | - Y Madhu Reddy
- Division of Cardiovascular Diseases, Center for Excellence in Atrial Fibrillation & EP Research, Bloch Heart Rhythm Center, Cardiovascular Research Institute, University of Kansas Medical Center, Mid America Cardiology, University of Kansas Hospitals, Kansas City, KS, USA
| | - Jayant Nath
- Division of Cardiovascular Diseases, Center for Excellence in Atrial Fibrillation & EP Research, Bloch Heart Rhythm Center, Cardiovascular Research Institute, University of Kansas Medical Center, Mid America Cardiology, University of Kansas Hospitals, Kansas City, KS, USA
| | - Dhanunjaya R Lakkireddy
- Division of Cardiovascular Diseases, Center for Excellence in Atrial Fibrillation & EP Research, Bloch Heart Rhythm Center, Cardiovascular Research Institute, University of Kansas Medical Center, Mid America Cardiology, University of Kansas Hospitals, Kansas City, KS, USA
| |
Collapse
|
8
|
Kavinsky CJ, McElhinney DB, Blankenship JC. SCAI Is the voice of congenital and structural heart disease interventionalists. Catheter Cardiovasc Interv 2016; 87:349-50. [DOI: 10.1002/ccd.26446] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Clifford J. Kavinsky
- Chair, SCAI Structural Heart Disease Committee, Rush University Medical Center; Chicago IL
| | - Doff B. McElhinney
- Chair, SCAI Congenital Heart Disease Council, Stanford University Medical Center; Stanford CA
| | | |
Collapse
|